Shots: The FDA has approved Imfinzi for an additional dosing option (1500mg, FD, q4w) in the approved indications of unresectable stage III NSCLC after CRT and prior treated advanced bladder […]readmore
Tags : P-lll
Shots: In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial in collaboration with the UK NIHR The P-lll ENSEMBLE 2 study […]readmore
Clinical Trials
COVID-19
Moderna’s mRNA-1273 Demonstrates 94.5% Efficacy in Preventing Symptomatic COVID-19
Shots: The P-lll COVE study involves the assessing of mRNA-1273 (100 µg dose level) in 30,000 patients with COVID-19 in the ratio of (1:1) aged > 18 yrs. in the […]readmore
Shots: The P-lll JADE REGIMEN study involves assessing of Abrocitinib (100/ 200mg) vs PBO in 1233 patients aged ≥ 12 yrs. in a ratio (1:1:1) with mod. to sev. AD […]readmore
Shots: Xbrane reported that the last patient has been enrolled into the P-III XPLORE study assessing Xlucane vs Lucentis in 580 patients with wet AMD The company will conduct an […]readmore
Shots: The P-lll CAN-COVID trial involves assessing Ilaris (canakinumab) + SOC vs PBO + SoC in 454 patients aged 18-98yrs. with COVID-19 pneumonia and cytokine release syndrome CRS, with its […]readmore
Shots: The P-lll DAPA-CKD study involves the assessing of Farxiga (qd, 10 mg) + SOC vs PBO in 4304 patients with CKD stages 2-4 and elevated urinary albumin excretion, with/ […]readmore
Shots: The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in […]readmore
Shots: The P-lll IM-UNITI LTE study involves assessing of Stelara (SC, 90mg, q8w/q12w) vs PBO as maintenance therapy in 1,281 patients with moderate to severe CD. All patients completing 44wks. […]readmore
Shots: The P-lll PENELOPE-B study involves the assessment of Ibrance vs PBO in addition to at least 5yrs. of standard adjuvant endocrine therapy in 1,250 women with HR+, HER2- eBC […]readmore